SpringerProtocols: Abstract: Real-Time PCR to Detect Minimal Residual Disease in Childhood ALL

Real-Time PCR to Detect Minimal Residual Disease in Childhood ALL

By: Cornelia Eckert², Olfert Landt³

Abstract

Full Text

Download PDF (121K)

Measurement of minimal residual leukemia at early time points during therapy has now been shown to predict reliably outcome in childhood acute lymphoblastic leukemia (ALL) (1-3). Consequently, ongoing European treatment protocols are using this technology to stratify therapy. Currently the most widely applicable and sensitive method for the detection of minimal residual disease (MRD) in ALL is polymerase chain reaction (PCR) of antigen receptor gene rearrangements. This technique relies on identification of the leukemia specific junctional sequence from amplification of diagnostic DNA. The sequence is then used either as a clone-specific probe or allele specific primer to detect MRD in DNA taken at times of remission.

Affiliation(s): (2) Department of Pediatric Oncology and Hematology, Charité Medical Center, Humboldt University of Berlin, Berlin, Germany
(3) TIB MOLBIOL, Berlin, Germany

Book Title: Pediatric Hematology: Methods and Protocols

Series: Methods in Molecular Medicine | Volume: 91 | Pub. Date: Sep-29-2003 | Page Range: 175-182 | DOI: 10.1385/1-59259-433-6:175

Subject: Molecular Medicine

References

Download References

1.	van Dongen, J. J., Seriu, T., Panzer-Grümayer, E. R., et al. (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukemia in childhood. Lancet 352, 1731–1738.

2.	Cave, H., van der mnWerff ten Bosch, J., Suciu, S., et al. (1998) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group. N. Engl. J. Med. 339, 591–598.

3.	Eckert, C., Biondi, A., Seeger, K., et al. (2001) Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukemia. Lancet 358, 1239–1241.

4.	mnPongers Willemse, M. J., Verhagen, O. J., Tibbe, G. J., et al. (1998) Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Leukemia 12, 2006–2014.

5.	Kreuzer, K. A., Bohn, A., Lass, U., Peters, U., and, Schmidt, C. A. (2000) Influence of DNA polymerases on quantitative PCR results using TaqMan probe format in the LightCycler instrument. Mol. Cell Probes 14, 57–60.

6.	Verhagen, O. J., Willemse, M. J., Breunis, W. B., et al. (2000) Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 14, 1426–1435.

7.	Szczepanski, T., Pongers-Willemse, M. J., Langerak, A. W., et al. (1999) Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood 93, 4079–4085.

8.	Pongers-Willemse, M. J., Seriu, T., Stolz, F., et al. (1999) Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 13, 110–118.

9.	Szczepanski, T., Willemse, M. J., van Wering, E. R., van Weerden, J. F., Kamps, W. A., and van Dongen, J. J. (2001) Precursor-B-ALL with D(H)-J(H) gene rearrangements have an immature immunogenotype with a high frequency of oligoclonality and hyperdiploidy of chromosome 14. Leukemia 15, 1415–1423.

Comments (Loading...)

Post comment/View all comments